The funding round was led by Maven Capital Partners and will support product development and marketing.
"Maven is delighted to maintain its support for iAM following the company’s consistent commercial growth in recent years. We’ve been impressed by the ambition and drive demonstrated by the management team, as well as the strong performance of both business units in developing compelling propositions and ensuring customer retention. Furthermore, we acknowledge the immense value within the sectors iAM’s divisions operate, which are currently undergoing substantial growth and witnessing robust merger and acquisition activity. This additional investment will enable iAM to further expand its client offering and achieve significant revenue scaling."
The financing round was backed by Maven Capital Partners, YFM Equity Partners, Triple Point Ventures, and regional funds to support US growth.
"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."
The Series A round was backed by YFM Equity Partners and Maven Capital Partners to support international expansion and product development.
"The demand we’re seeing for our technology to solve a genuine problem, experienced by all businesses that deal with contracts, has been extraordinary. It’s clear that most businesses have a challenge when it comes to scaling contract processes and making the entire process much easier and faster. Bolstered by YFM’s support, we are in prime position to develop our game-changing approach to digital contracting even further."
The seed round was backed by Mercia and Maven Capital Partners to accelerate product development.
"Plexus Innovation is on a mission to replace manual measurements and make remote monitoring the norm. The initial funding round enabled Steve and Ian to build their team and establish their presence within the social housing and care sectors. The latest investment will enable them to roll it out to a much wider range of clients."
Maven Capital Partners has backed the software provider to support product development and team expansion.
"We believe that Zinc offers an excellent opportunity for investment into a scaling business that is operating in a market supported by positive sector dynamics. The Company is led by a very capable team, and they have made good commercial progress to date. Revenues are backed up by strong recurring revenues and a positive deal pipeline of prospective new clients. We are delighted to have structured a debt and equity solution which will support the delivery of management’s ambitious targets."
